oved treatments has left many without options. With nemolizumab’s targeted mechanism of action and promising results in related conditions, we’re hopeful this study will pave the way for a new therapeutic approach for those living with CPUO.”

BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.

GLOBAL HEAD OF R&D

GALDERMA










More information about the study is available on theclinicaltrials.govwebsite.

About nemolizumab
Nemolizumab was approved in August 2024 by the United States Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis.3In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately cont
=*=*=*=*=*=
当前为第5/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页